Exicure Inc./$XCUR
1D1W1MYTD1Y5YMAX
Capital at risk
About Exicure Inc.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
- Ticker
- $XCUR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1
- Headquarters
- Redwood City, United States
- Website
- www.exicuretx.com
Exicure Inc. Metrics
BasicAdvanced
$8.1M
-
-$1.30
3.66
-
Price and volume
Market cap
$8.1M
Beta
3.66
52-week high
$9.48
52-week low
$1.05
Average daily volume
42K
Financial strength
Current ratio
0.557
Quick ratio
0.414
Interest coverage (TTM)
-7,309.00%
Profitability
EBITDA (TTM)
-7.11
Effective tax rate (TTM)
7.11%
Management effectiveness
Return on assets (TTM)
-30.32%
Return on equity (TTM)
-168.37%
Valuation
Price to book
8.02
Price to tangible book (TTM)
-1.09
Price to free cash flow (TTM)
-1.225
Free cash flow yield (TTM)
-81.60%
Free cash flow per share (TTM)
-1.004
Growth
Earnings per share change (TTM)
-29.01%
3-year earnings per share growth (CAGR)
-19.37%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.